Celebrating 30 years of fostering global partnerships in the life sciences, this year’s BIO-Europe conference has taken on a distinctly Swedish flavour with a special nod to ABBA. The iconic biotech gathering, nowadays held in Stockholm is not only a celebration of three decades of collaboration but also a showcase of innovation at the heart of the industry. The IOCB Tech Family, Prague.bio and other companies are proud to represent the Czech biotech sector at this landmark event, where ABBA-themed sessions are sparking creative discussions and new partnerships.
As part of the Czech delegation’s presentation, IOCB Tech Family has introduced its latest member, PharmTheon – a new high-tech translational research centre based in Prague. PharmTheon’s advanced facilities and interdisciplinary expertise across organic chemistry, molecular biology, and AI-driven drug development mark a significant step forward in fostering innovation within the Czech biotech landscape.
Alongside showcasing leading Czech biotech research and technology transfer capabilities, Prague.bio is also generating interest in its own annual conference held in Prague. This conference serves as a networking platform that unites science and business in Central Europe, and has been met with enthusiastic interest from BIO-Europe participants.
“Apart from spreading the good word about Prague.bio Conference, BIO-Europe helps us to become integral part of the European biotech scene and to bring similar events to Prague,” said Jiri Fusek, Managing Director of Prague.bio. “We are also delighted to see there is a growing number of Czech participants, which brings more attention to the Czech biotech ecosystem.”
The Czech booth also enjoys support from the Czech Embassy in Stockholm, highlighting the government’s commitment to promoting the country’s biotech sector.
Together with IOCB Tech Family and Prague.bio, other Czech companies are also present at the stand. It is among them Sotio, which is committed to developing immuno-oncology therapies; BioCanim, a spin-off aimed at treating solid tumours with an ultimate goal the pancreatic cancer; Bioinova producing drugs from stem cells, or DIANA Biotechnologies focused on diagnostics, molecular biology and antibody development.
BIO-Europe remains Europe’s largest and most influential partnering event for the life sciences industry, attracting key stakeholders from all over the world. This year’s edition has set impressive records, with 6000 attendees from over 60 countries, more than 30 000 one-on-one meetings, over 4 000 licensing opportunities posted, ca 3000 companies represented, almost 80 company presentations, and nearly 200 exhibitors. These numbers underscore the conference’s crucial role in fostering international collaboration and driving advancements in biotechnology and pharmaceutical innovation.